Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Exelixis Completes Enrollment in mCRPC Trial | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Exelixis Completes Enrollment in mCRPC Trial

COMET-1 to test cabozantinib in prostate cancer

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Exelixis has reached the enrollment target of 960 patients has been reached for COMET-1, the company’s Phase III trial of cabozantinib in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint of COMET-1 is overall survival. Exelixis expects top-line data from COMET-1 and a second pivotal trial in mCRPC, COMET-2, in 2014.

COMET-1 is a randomized, double-blind, placebo-controlled trial designed to enroll  patients with mCRPC who have previously been treated with docetaxel, abiraterone acetate and/or enzalutamide. All patients in the trial have bone metastases and there is no limit to the number or type of prior treatments. Patients are randomized 2:1 to receive cabozantinib or prednisone. The trial is event-driven and has 90% power to detect a 25% reduction in the risk of death at the time of final analysis, which requires 578 events. A single interim analysis after 387 events is also planned and will assess if the trial achieved its primary endpoint; it will not include a futility analysis. The secondary endpoint of the trial is bone scan response as assessed by an independent radiology facility (IRF).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics